NIAID-Led Study of mRNA Vaccine Supports Advance to Phase 3 Human Trials
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc., Cambridge, Massachusetts. The animal study results published online today in the New England Journal of Medicine complement recently reported interim results from an NIAID-sponsored Phase 1 clinical trial of mRNA-1273. The candidate mRNA-1273 vaccine is manufactured by Moderna.
In this study, three groups of eight rhesus macaques received two injections of 10 or 100 micrograms (µg) of mRNA-1273 or a placebo. Injections were spaced 28 days apart. Vaccinated macaques produced high levels of neutralizing antibodies directed at the surface spike protein used by SARS-CoV-2 to attach to and enter cells. Notably, say the investigators, animals receiving the 10-µg or 100-µg dose vaccine candidate produced neutralizing antibodies in the blood at levels well above those found in people who recovered from COVID-19.
The experimental vaccine also induced Th1 T-cell responses but not Th2 responses. Induction of Th2 responses has been associated with a phenomenon called vaccine-associated enhancement of respiratory disease (VAERD). Vaccine-induced Th1 responses have not been associated with VAERD for other respiratory diseases. In addition, the experimental vaccine induced T follicular helper T-cell responses that may have contributed to the robust antibody response.
Four weeks after the second injection, all the macaques were exposed to SARS-CoV-2 via both the nose and the lungs. Remarkably, after two days, no replicating virus was detectable in the lungs of seven out of eight of the macaques in both vaccinated groups, while all eight placebo-injected animals continued to have replicating virus in the lung. Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure. This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note. A COVID-19 vaccine that reduces viral replication in the lungs would limit disease in the individual, while reducing shedding in the upper airway would potentially lessen transmission of SARS-CoV-2 and consequently reduce the spread of disease, they add.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Moderna Reports 71% Enrollment in Coronavirus Vaccine Trialon September 5, 2020 at 4:42 pm
Moderna (NASDAQ:MRNA) continues to make progress enrolling patients in the phase 3 clinical trial testing its coronavirus vaccine, mRNA-1273. In its weekly update, the biotech said 21,411 patients ...
- COVID-19 vaccine won’t alter your DNA: Widely shared misinformation is not trueon September 5, 2020 at 1:43 pm
Did you see a post on social media about the new COVID-19 vaccine? That you will essentially become a genetically modified human being? Not so, the experts say.
- NOT REAL NEWS: False stories from this week about Biden, vaccines, missing children and moreon September 5, 2020 at 9:10 am
In the video, Bennett appears to go off script during a question and answer period, saying: "I'm just going to be honest, Mr. Biden, I was told to go off this paper, but I can't. We need the truth and ...
- No, a new COVID-19 vaccine won’t alter your DNAon September 5, 2020 at 8:51 am
Social media posts claiming the coronavirus vaccine will change people into genetically modified human beings aren't true, experts say.
- Moderna Pulling Back on Coronavirus Vaccine Trial Enrollment to Get More Minority Patients Involvedon September 4, 2020 at 7:42 pm
A world eager for progress on vaccines to guard against the SARS-CoV-2 coronavirus and/or COVID-19 might have to wait a bit longer for a breakthrough. The CEO of Moderna (NASDAQ:MRNA), the developer ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Moderna loses key patent challengeon September 4, 2020 at 4:07 pm
A dispute over a key technology used in Moderna’s highly anticipated COVID-19 vaccine came to a head in July when Arbutus Biopharma fended off a claim by the vaccine maker. The patent clash over the ...
- Gov't Contracts Of The Month: Vaccines, Space, AI Researchon August 31, 2020 at 3:15 pm
The federal government continued to funnel billions of dollars into the development of COVID-19 vaccines while the White House announced goals to advance artificial intelligence and quantum ...
- Newark Mayor Says Coronavirus Vaccine Trial Causing Fear In Cityon August 31, 2020 at 3:13 pm
Would YOU volunteer to test a potential coronavirus vaccine? A national study on mRNA-1273 is raising serious questions in Newark, NJ.
- Moderna May Supply 40M Coronavirus Vaccine Doses to Japanon August 31, 2020 at 8:38 am
Moderna (MRNA) is negotiating a deal with Japanese authorities for supply of its coronavirus vaccine in Japan, following a potential approval.
- Moderna In Talks To Supply 40M Doses Of Its Covid-19 Vaccine To Japanon August 31, 2020 at 7:16 am
Moderna confirmed that it is engaged in discussions with the Ministry of Health, Labour and Welfare of Japan (MHLW) to potentially purchase 40 million or more doses of its mRNA-1273 vaccine candidate ...